Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic ...

Read here for an analysis of Synaptics' FY24 revenue decline, growth projections, competitive positioning, and valuation, ...

The BMW Group presents the driving and user experience of the future at the Consumer Electronics Show (CES) 2025 in Las Vegas ...

Applications are now open for the free New York Portfolio Review which is produced by The New York Times photo department, ...

Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase ...

While both Progress and Kichler will operate as part of the same corporation, each will continue as independent brands. Both brands will now be represented by a singular rep agency sales force with ...

CES, with lagging advancements. Find out why MBLY stock’s valuation suggests better buying potential around $12.

Model portfolios continue to expand, increasing to nearly $424 billion USD. Assets in model portfolios have surged by 48% over two years, reflecting their growing popularity and effectiveness in ...

Tome.app focuses on storytelling by helping you create dynamic and interactive presentations. It’s great for those who need flexibility in slide design. Design.ai is a versatile tool that offers ...